Last update Dec. 23, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Siponimod, Siponimod Fumarate in other languages or writings:
Siponimod, Siponimod Fumarate belongs to this group or family:
Main tradenames from several countries containing Siponimod, Siponimod Fumarate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 84 | % |
Molecular weight | 517 ; 1.149 | daltons |
Protein Binding | 99.9 | % |
VD | 1.77 | l/Kg |
pKa | 3.33 | - |
Tmax | 4 (2 - 12) | hours |
T½ | 30 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Amamanta of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an immunomodulator with actions similar to those of fingolimod, but has a shorter half-life. It is used in the treatment of patients with relapsing forms of multiple sclerosis. Oral administration once daily.
At the date of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, moderately high molecular weight, -more so in the case of fumarate-, and very high percentage of binding to plasma proteins) make passage into breast milk in significant quantities very unlikely.
Since its side effects can be frequent and severe, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
If administered during breastfeeding, it is advisable to monitor the appearance of symptoms (vomiting, diarrhea, poor feeding, irritability...) in the infant. (Mother 2024)
See below the information of this related product: